New Jersey recruits Mark Cuban to tackle health benefits cost spiral

The Cost Plus Drugs co-founder is joining a state working group targeting PBM opacity and drug costs

Commercial risk teams are responding with tighter controls, scenario modeling, and broader collaboration across underwriting, claims, and cyber operations.

Leaders continue to prioritize resilience planning while balancing cost, coverage terms, and operational exposure in a changing market cycle.